Q1 2025 Masimo Corp Earnings Call
At this time, all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. I'm pleased to introduce Eli Kammerman,
Thank you.
Speaker Change: Hello everyone, joining me today are senior Katie Diamond and CFO Micah Young.
Speaker Change: Before we begin, I'd like to inform you that this call will contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in our periodic filings with the SEC.
Speaker Change: Also, this call will include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles or debt.
Speaker Change: We generally refer to these as non-GAAP or adjusted financial measures. In addition to GAP results, these non-GAAP financial measures are intended to provide additional information to enable investors to assess the company's operating results in the same way management assesses such results.
Speaker Change: It is important to note that the San United business is now being classified as help for sale and reported it in discontinued operations.
Speaker Change: As a result, our non-GAAP financial measures have been updated to reflect the continuing operations of Masimo's healthcare business for both current and historical reporting periods. Therefore, the financial measures we will be covering today will be primarily on a non-GAAP basis unless noted otherwise.
Speaker Change: Reconciliation of these measures to the most directly comparable GAAP financial measures are included within their earnings release, earnings presentation and supplementary financial information on our website.
Speaker Change: Investors should consider all of our statements today, together with our reports filed with the FCC, including our most recent form, 10K and 10Q, in order to make informed investment decisions. I'll now pass the call to Kate's assignment.
Katie Szyman: Thank you, Eli, and good afternoon, everyone. Since 20, Masimo was early, as CEO nearly three months ago, I've been focused on immersing myself in our business.
Katie Szyman: I visited customers at ten hospitals in five cities that was more than two-thirds of our employees across the US and Europe toward numerous manufacturing and R&D sites evaluated their innovation pipelines and intended national meetings with our sales teams.
Katie Szyman: I have three key takeaways in these trips. One, our technology advantage is real. Not only are our existing products market meters for a reason, but there's also excitement and a strong commitment to innovation throughout the organization that will be essential to our future growth.
Katie Szyman: Second, we have a stellar team that is enthusiastic about the path forward at Masimo. Our people believe in our mission and our focus on delivering for our patients.
Katie Szyman: Our teams use the momentum we have and they watch build on it.
Katie Szyman: Third, we have an opportunity to do better. This shouldn't come as a surprise to anybody. Improvement is always possible, but there are areas of our business where I believe by pulling the right leathers, levers, we can be more effective.
Katie Szyman: Specifically, we can bring a new level of commercial excellence to the organization and how we go to market. Further, as we refocus our innovation, we can also put the right processes and plans in place to ensure we consistently have successful product launches that deliver meaningful results.
Katie Szyman: Now let me turn to the quarterly results. The headline is that this is another strong quarter and our performance clearly demonstrates the earnings power of our core healthcare business. We deliver double digit revenue growth and EPS growth of more than 50%.
Katie Szyman: For the first quarter, our healthcare revenue of $371 million grew 10% on a constant currency basis. This was paired with meaningful operating margin expansion of 750 basis points.
Katie Szyman: Micah will go through the results more fully, but I did want to make sure to highlight that I'm excited to be joining Masimo at a moment where we can build and improve from a position of meaningful strength as clearly demonstrated by this quarter's results.
Micah Young: Next, I want to highlight some significant milestones from the quarter beyond the financials.
Katie Szyman: First is the announcement we made today that we have reached an agreement to divest our consumer audio business, also known as Sound United. This represents important progress as we continue to refocus on our professional healthcare business.
Katie Szyman: With this failed process concluded, we are well positioned to dedicate our time and resources to meeting patient needs while investing in innovation.
Katie Szyman: Our Consumer Audio business and its talented team will be well positioned for growth and success under Harmon's leadership.
Micah Young: Michael will speak in a bit more detail to the thoroughness of the process that we went through in reaching this agreement and why we believe this was the right transaction for our shareholders and our sound United team.
Micah Young: Second, I speak to announce that Lisa Hellman has joined our team as our new Chief Human Resources Officer.
Micah Young: One of the many benefits of building out such a strong base is the exceptional talent we're able to attract that joins the Masimo team to help us on our next chapter of growth. Lisa is an outstanding addition to our team and is focused on building our culture, fostering strong engagement and developing our amazing talent.
Micah Young: Third, I also want to touch briefly on an incident that has impacted our website and several of our systems beginning last week.
Micah Young: The investigation is ongoing, but as of right now, we do not expect that this will have an impact on our guidance. We voluntarily filed a form A.K. with the SEC around a situation, and you can refer to that for further details.
Micah Young: Finally, I would like to take a moment to comment on our strategic and financial goals and what we are doing to achieve that.
Micah Young: We are seeking to invest in our core healthcare business in order to accelerate revenue growth over time beyond our long-standing revenue growth target of 7 to 10%. Currently, we see a number of ways we're going to accomplish this.
Micah Young: First, we plan to upgrade our existing sensors and create next-generation monitors enabled with our AI-based advanced algorithms. We will utilize the advanced algorithms that our team has already developed over the years to enable every patient to be continuously monitored in the acute and post-acute care environment.
Micah Young: Lastly, we will focus on growth and commercial excellence in our global markets by shifting the structure of our sales forces from being centralized by product categories to regionally focused groups responsible for selling our broader portfolio.
Micah Young: We look forward to sharing more about these efforts that are at investor day, which we anticipate scheduling in the fourth quarter of 2025. So please stay tuned.
Micah Young: Before I wrap up, I'd like to spend a moment on tariffs. Our first priority is to ensure supply of products to our customers globally.
Micah Young: We've been dedicating time and resources to assessing and planning for potential tariffs on our various scenarios, given the very fluid situation. Our operations and finance teams have quantified the potential impact and are working diligently through the situation, including scenario planning and developing mitigation plans.
Micah Young: We will adjust our supply chain strategy and implement specific mitigation plans, once we believe there's sufficient clarity to commit to a mitigation path. Michael will cover this in more details.
Micah Young: I do want to call out, however, how impressed I am by the Massimo team and their ability to move efficiently and promptly as new events arrive.
Micah Young: While tariffs may represent a curveball, the Massimo team has proven itself at depth at handling and executing to her any variety of situations over these last few years.
Micah Young: Additionally, as this quarter only further demonstrates, the high recurring revenue and durable growth profile of our business positions us particularly well to navigate whatever broader macro uncertainties may come our way.
Micah Young: I really like to thank our entire team for delivering another excellent quarter. Our products and technologies continue to impact millions of patients around the world. I feel honored to be a part of this team.
Micah Young: With that, I'll pass it back to Micah. Thank you, Katie, and good afternoon, everyone. For the first quarter, as Katie mentioned, healthcare revenue was 371 million, up 10% on a constant currency basis.
Micah Young: Our Consumble and Service Revenue grew 8% and our Capital Equipment and other revenue grew 32%.
Micah Young: The timing of shipments related to a large tender contract renewal resulted in higher than expected capital sales, as well as lower than expected consumable sales this quarter. We expect the timing of these shipments to normalize throughout the year and align with our full year expectations for both consumable and capital sales.
Micah Young: We also ship more than 72,000 technology boards and monitors during the quarter, which is above our expected range due to strength in our core business and also in part to the timing of shipments related to the large tender contract I just mentioned.
Micah Young: Moving down the TNL, our gross margin of 63.1% improved 80 basis points year-by-year driven by operational efficiencies and product cost reductions.
Micah Young: Our operating margin of 28.8% improved 750 basis points year-by-year as a result of the actions we took last year to optimize our cost structure and refocus on our core business.
Arnon Gap Earnings for Share was $1.36.
representing 56% growth, versus the prior year. [inaudible]
Micah Young: On a gap basis, our net income from continuing operations was $47 million or $0.86 per share.
Micah Young: Our net loss from this continued operations was 218 million or $4.04 per share. This included an impairment charge of 295 million to intangibles for the audio business.
Micah Young: On a consolidated basis, our net loss was 171 million or $3,017 per share.
Micah Young: Now moving to our updated Disco 2025 financial guidance, a revenue estimate remains unchanged at a range of 1,500,000,000 to 1,530,000,000, reflecting 8% to 11% constant currency growth versus the prior year.
Moving down the P&L.
Micah Young: For comparison purposes to our previously issued guidance, we excluded the impact of new tariffs and I'm going to begin with our updated guidance excluding new tariffs followed by our updated guidance that now includes the new tariffs before any mitigation.
Micah Young: Excluding new tariffs, our updated guidance implies operating margins of 28% to 28.5%, reflecting an increase of 50 basis points at the midpoint versus our prior guidance.
Micah Young: Now, including new tariffs, but before any mitigation, we are updating our guidance for operating margin to be in the range of 25.5% to 26.4%. And earnings per share to be in the range of $4.80 to $5.15.
Micah Young: Terrace represent a 210 to 250 basis point impact to operating margin and a 45 to 50 cent impact to EPS.
Micah Young: This projected 33 to 37 million increased the cost of cells for fiscal 2025 assumes that the low end 25% for non-USMCA eligible products.
Micah Young: A baseline rate of 10% for products made in Malaysia, and 170% for raw materials and cables sourced from China.
Micah Young: Behind of the range assumes that reciprocal tariffs related to our manufacturing in Malaysia are implemented after the current 90-day pause period expires.
Micah Young: Given that tariff costs are capitalized into inventory and then recognized as products are sold, we expect the impact of tariffs to increase each quarter over the remainder of the year, starting with a $2 million impact in the second quarter.
Micah Young: Breaking down the impact, deterred impact further, products manufactured in Mexico and not currently eligible for USMCA exemption represent approximately 10% of our total cost of goods sold.
Micah Young: Product Manufacturing and Malaysia that are subject to US tariffs represent roughly one third of our total cost of sales.
Micah Young: Finally, we want to call out that about 5% of our cost of sales represents raw materials and cables sourced from China.
Micah Young: Even though these components represent a small portion of our cost of sales China tariffs represent up to 50% of our total tariff impact due to the high rate being imposed.
Micah Young: Therefore, any progress in trade negotiations with China could have a significant impact in reducing our tariff exposure. We understand the current impact will not be acceptable longer term and will take mitigation steps depending on how the situation involves.
Micah Young: Any offsets from tariff negotiations, or product exemptions, or any benefits of a weaker dollar. Therefore, one should not annualize a tariff impact or use a testimony to our 2026 earnings.
Micah Young: Moving on to our cell of San United, while we at Masimo were certainly a motivated celler so that we could refocus our strategy to areas where we could best deliver meaningful value to our shareholders, shareholders should take comfort that today's transaction reflects full fair market value.
Micah Young: We conducted a thorough comprehensive process led by Centerview and Morgan Stanley , that involved a large group of potential buyers and significant negotiations. Thank you very much.
Micah Young: Through this process, we arrive at the most optimal transaction available for shareholders and we are pleased to have this chapter behind us.
Micah Young: The transaction is expected to close by the end of the year, subject to obtaining necessary regulatory clearances. Regarding the use of proceeds, we anticipate prioritizing share repurchases.
Micah Young: In closing, our first quarter results clearly demonstrate the underlying growth potential and earnings leverage we expect to achieve throughout this year.
Speaker Change: I also want to take a moment to call out that Katie has been embraced by the Masimo team and we are enthusiastic about her leadership.
Speaker Change: and short, Masimo Loth to a strong start to the year. And I've never been more excited to be a part of this team. With that, we'll open the call to questions. Operator.
Thank you.
Speaker Change: Thank you. Ladies and gentlemen, we will now begin the question and answer session. At this time, I would like to remind everyone to ask a question, please press the star button followed by the number one on your telephone keypad. If you would like to withdraw your question, please press star one again. One moment please for your first question.
[inaudible]
Speaker Change: Your first question comes from the line of Frederick Wise of Steed, please go ahead.
Speaker Change: Based on your commentary about the large tender in the quarter Micah can you give us a sense of.
Speaker Change: How big was it.
Speaker Change: What impact did it have on revenues and margins.
Speaker Change: <unk>.
Speaker Change: Our board.
Speaker Change: How do we normalize.
Speaker Change: And therefore I.
Speaker Change: Think about the cadence and implications for the second quarter as we start to.
Speaker Change: Extrapolate forward.
Rick: Yeah. Thanks, Rick.
Rick: Yes, so you kind of normalize for the quarter, a little bit I mean looking at it.
Rick: View without when you exclude the large tender contract.
Rick: The rest of our business is performing very well, we're seeing consumable.
Rick: And service growth of double digits.
Also seeing capital and other revenues growing high single digits and Thats. When you when you kind of back out the timing of that large tender and keep in mind, we still expect to recognize fully the revenue from that tendered tender that we expected as we were coming into the year, but that's just going to occur over the next several quarters. So.
Rick: So that is more of a timing issue, but if you kind of strip that backed out and look at it the <unk>.
Rick: The business is performing very well also our shipments we're seeing very good demand early in the year. It's still very early to get ahead of ourselves with increasing the guidance range or are our expectations I guess for for drivers for this year.
Rick: Yes.
Rick: If you look at it without the tender.
Rick: And kind of normal or normalized for that tender, we are still above at or above the high end of our range on drive our expectations for the quarter. So.
Rick: Okay.
Rick: And so just.
Rick: It's not fair.
Rick: That's for a little more give me Ken.
Rick: <unk> sales move up move higher sequentially.
Rick: Like.
Rick: Flat to up despite this excellent really superb first quarter and the and the tender.
Rick: Fuel in the tank for that are we're going to step lower.
Rick: Yes, I mean, the way to think about it is.
Rick: If you recall from last quarter, we mentioned that there is an extra 50 <unk> week in the fourth quarter that represents about 1% of our revenues. This year, if you back that out.
Rick: And then kind of look at historical seasonality, it's usually about 24, 5% give or take.
Rick: Each quarter in the first.
Rick: Three quarters of the year and then it steps up to closer to 26, 5% in Q4 so.
Rick: We expect normal seasonality of the business. This year, that's kind of how we've we've set the guidance and the range. So.
Rick: That should give you an idea of kind of how to think about Q2, but typically Q2 is either flat.
Rick: Flat to slightly down sequentially.
Rick: And if I could just sneak in one more on tariffs.
Rick: I know, it's way too early to talk about 2026.
Rick: And particularly from a tariff point of view, but we're all going to have to play with our model from a tariff perspective, we've done this over the last couple of weeks with other companies do we try to find.
Rick: Quarter number in terms for next year based on what we know or how should we approach it.
Thank you it's too early to it's definitely too early to annualize at this point I mean, we have mitigation plans that we're going to start to enact some of those plans are no regret actions that we're trying to that we've already identified and we're going to start to execute the tricky part is of course, the timing of this does flow through inventories and throughout the year and we're in a.
Rick: Short period of time to impact 2025.
Rick: We're hopeful that these actions will start to set us put us in a good position as we exit 2025.
Rick: And there's a lot that could change I mean, this is a very fluid environment.
Rick: Trade negotiations or we're expecting to see some of those things come into play here over the next.
Rick: I guess it was 90 days for about a month ago. So so we will see a lot more play out but.
Rick: It's too early to annualize the impact into next year, given the mitigation plans and the fluid environment, we're seeing.
Rick: Danielle. Thank you Rick just a disproportionate weighting of China in our tariff impact in cell.
Speaker Change: We just think those rates are.
Speaker Change: The likelihood that they may teams, that's correct and if you if you recall in China, the baseline rate back in 2020 that.
Speaker Change: Already have some of that in our run rate.
Speaker Change: That was about 25% I think on.
Speaker Change: Sometime in March that they implemented an additional 20% so.
Speaker Change: Before they added that extra 125 on top the rate was setting around 45% so.
Speaker Change: There could be potential that it goes down closer towards that rate, we don't know.
Speaker Change: Thanks again.
Speaker Change: Your next question comes from the line of <unk> Chopra with Wells Fargo. Please go ahead.
Chopra: Oh, Hey, good afternoon. Thanks, so much for taking the questions. Two for me. So Michael I. Appreciate all of you said about the tariffs, but I'm just curious whether you expect the impact of tariffs to have an impact on your long term operating margin goals are those still on the table and adequate follow up please.
Speaker Change: Yes.
Speaker Change: I feel very good about the underlying business. So let's start there we're performing very well. This year you saw 750 basis points of margin expansion in Q1.
For the full year were were.
Speaker Change: Estimating that guidance range. It implies over 430 basis points of margin expansion at the low end of the range. So.
Speaker Change: So we're.
Speaker Change: We're tracking very well, we're guiding core underlying margins at 28% to 25% we've continuously uplift at that over the past few quarters.
Speaker Change: And we're I'd say, we're hitting on all cylinders there.
Again, it's early on the tariff side, but we are.
We're standing by with these plans in enacting some of those plans to mitigate the tariff impact and I think.
Speaker Change: No a lot more as we move through the year.
Speaker Change: Yeah.
Speaker Change: Okay. Thank you and then my follow up question is congrats on the announcement to sell United.
Speaker Change: Just curious if the price you received was in line with your expectations into the plan is still to repay debt or our share buyback on the table as well. Thank you.
Speaker Change: Thank you Vic.
Speaker Change: So let me start with the valuation.
Speaker Change: Given the current macro economic environment, and kind of where where we see the landscape. Today. This is a very competitive process.
Speaker Change: It started out with a lot of potential a large amount of potential buyers.
Speaker Change: And we believe that we got to evaluation that was the right fair market value.
Speaker Change: And.
Speaker Change: And in terms of how we use those proceeds we're definitely prioritizing share repurchases that'll be a focus for us as we look to close out the transaction later this year.
Speaker Change: Operator next question please.
Speaker Change: Your next question comes from the line of Jason Bednar with Piper Sandler. Please go ahead.
Jason Bednar: Hey, good afternoon, guys. Congrats on a really strong core here.
Speaker Change: Start the year.
Jason Bednar: Apologize for any background noise I'm traveling here today.
Speaker Change: But wanted to see if you could first start talking to us about what you're hearing from OEM partners with respect to hospital Capex spending of hospital spending in patient monitoring and connected care.
Speaker Change: Judging by your results here Board numbers I'm sure I know the answer but I'd just love to hear any additional color. There and then I. Appreciate you don't want to get into the details of your investigation, but just if you can help us a bit at all but.
How do you have the confidence here and saying you don't expect it to impact your guidance and then I'll have one more follow up.
Speaker Change: Yeah. Thanks, Jason So let me, let me start out with the Oems and the drivers. So we're very encouraged are encouraged by the results we saw in Q1.
Speaker Change: Very solid underlying demand, even when you strip out that timing that we talked about on the tender contract.
Speaker Change: Again, we don't want to get ahead of ourselves, but I think the way to think about this is we are a high recurring revenue business.
Speaker Change: We only have about 10% to 15% of our revenues give or take on how that kind of fluctuate.
Speaker Change: Our tightened capital.
Speaker Change: Capital equipment and other revenue so so I think.
Speaker Change: That's one way to look at this we're not very highly dependent on capital too.
Speaker Change: The cost of our capital is a lower cost in terms of in terms of capital budgets for hospitals relative to some of the higher cost monitors and machines that are out there. So.
That's one way to really look at this in and like I said, there's no we're not seeing any signals of softness at this point in the year and we're encouraged by where things are heading we just don't want to get ahead of ourselves in terms of our guidance, we want to be thoughtful and prudent about that.
Speaker Change: <unk>.
Speaker Change: On the on the second topic.
Speaker Change: Currently we we view the situation, where we're doing everything we can in terms of working through our protocols. We've got strong protocol there based on what we know today and we have no evidence that there is any sensitive employee data patient data that is impacted.
Speaker Change: And of course, we will provide updates as required there.
Speaker Change: The other thing is is.
Speaker Change: We're as we worked through those protocols were encouraged by the progress, we're making so far and bringing systems back up and running.
Speaker Change: And again.
Speaker Change: Just want to reiterate that as we see it today, we do not believe this is impacting our guidance for the year.
Speaker Change: Okay.
Speaker Change: Okay.
I know, it's sensitive topic and I appreciate the extra color there Mike.
Speaker Change: Maybe ill throw in my own tariff question.
Speaker Change: Just if there's anything you can give us around near term long term mitigation options that might be in front of you that youre contemplating it sounds like there's some things that are here that are.
Speaker Change: Fairly real time that youre going to be implementing soon and maybe specifically just given the sensitivity on China.
Speaker Change: Can you speak to maybe the ease or difficulty you have in changing your sourcing or moving to dual sourcing.
Speaker Change: With respect to some of your partners there on product.
Speaker Change: Yes, let me start out with.
Speaker Change: Like I said, we have some actions that we can take more in the near term.
Speaker Change: Some of those actions are altering some of our product sourcing manufacturing supply chain.
Speaker Change: We're also evaluating pricing opportunities.
Speaker Change: And that's both in the kind of the near term and the longer term.
Speaker Change: And.
Speaker Change: We're also encouraged by the integration we have the vertical integration we have in manufacturing we have a semiconductor plant in the U S and there may be some things we can do there to to.
Speaker Change: To expand that capability.
Speaker Change: And evaluate that more on a kind of a product by product basis.
Speaker Change: The other thing I would say is in terms of China, that's something that we are working through and evaluating the mitigation plans.
Speaker Change: That involves of course, the raw materials. There there are opportunities to move that that one may be a little bit.
Speaker Change: Not going to be immediate or near term, but.
Speaker Change: We do believe we have some opportunities to to shift that over time so.
Speaker Change: I think we're going to know a lot more as we move through these plans this year and hopefully have more and more updates and put us put ourselves in a better spot in terms of how we exit the year and head into 2026.
Speaker Change: Great. Thanks, so much.
Speaker Change: Youre welcome.
Speaker Change: Your next question comes from the line of Mike Matson with Needham. Please go ahead.
Speaker Change: Yeah. Thanks I.
Speaker Change: I guess first just with the.
Speaker Change: The proceeds from the sale of the consumer audio business.
Speaker Change: You said your preferences to do share repurchase so just curious why you're opting for that versus repaying some of the debt.
Speaker Change: So maybe allow you more balance sheet flexibility, if you want to do M&A or something like that in future.
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: Mike we're evaluating all options there right now.
Speaker Change: That's that's an area that we're prioritizing but it also depends on.
Speaker Change: As we evaluate the economics right.
On interest rates it depends on.
Speaker Change: Where the share prices as well.
Speaker Change: Among other factors, so, but we do.
Speaker Change: Expect to prioritize share buybacks and return that to shareholders as well so.
Speaker Change: Okay. Thanks.
Speaker Change: I wanted to ask one on the hemodynamic monitoring opportunity given kt's background.
Speaker Change: Maybe you can talk a little bit more about how big that market is in.
Speaker Change: Where your share is and you know where do you think it can go and how youre going to kind of differentiate yourselves.
Hemodynamic monitoring.
Speaker Change: So yes, thanks for the question.
Speaker Change: First of all relative to the hemo dynamic market as you recall the maximal position really comes from the acquisition of <unk> that was done several years ago.
Speaker Change: Super small presence in that market. So what we're really doing is just kind of putting the ability to do hemodynamic monitoring onto our mainline monitor and what we've decided to do at this point in Q2 launch settled fully in 2026 and beyond with our Nextgen monitoring system.
Speaker Change: Really comment obviously about the size of the market, but I would say, it's fair to assume that we have almost very very small.
Speaker Change: <unk> today and that we're optimistic that when we can get it onto the right platform over time that there would be the opportunity.
Speaker Change: To have a more significant presence in hemodynamics.
Speaker Change: Unlike kind of the competition ours is really about kind of ease of use and kind of your mid to low acute patient and not necessarily your high acuity acuity patients in that market. So it's a little bit of a different strategy.
Speaker Change: Well, we really offer is the strength in pulse ox and kind of balanced the hemoglobin based delivered oxygen measurements that we talked about in the past about <unk> and being able to kind of combine the pulse ox together with hemodynamics.
Speaker Change: He said more towards your medicine volatility type patients and so that's our overall plan over time, but that's going to be really fully launched as we get into next year.
Speaker Change: Okay got it thank you.
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: Your next question comes from the line of Matt Taylor of Jefferies. Please go ahead.
Speaker Change: Hi, Thanks for taking the question and congrats on a good quarter, despite the tariff issues here, but.
Speaker Change: Got a couple of clarification questions. So.
Speaker Change: The first one just to start with the underlying margin expansion you did see a nice another step up here.
Speaker Change: All of that.
Speaker Change: Actions that you talked about it going back a year ago.
Speaker Change: You have to kind of come to fruition to get too close to or ahead of your goal and I. Just wanted to know on an underlying basis as there is still more low hanging fruit to get in terms of operating margin expansion. So that's the first one.
Speaker Change: Yes, Thanks, Matt.
Speaker Change: Yeah, I'd say I mean, if you look at our business model I mean, we do have a high leverage business model, but we are also trying to make sure that we're making the right investments throughout this year to continue to drive growth on the top line. So.
Speaker Change: There will some of those investments we will start to play in through the second quarter through the fourth quarter, but.
Speaker Change: So we're trying to strike that right balance this year I mean, if you look at the full year were again were over 430 basis points of margin expansion.
Speaker Change: And at the same time, making some good investments within ourselves and marketing teams as well as certain R&D projects that we want to kind of refocus back on too. So so we're striking the right balance here and I think it's going to set us up well as we move forward.
Okay.
Speaker Change: On the tariffs.
Speaker Change: <unk> had a little bit of a different approach to some of the other companies. When you gave the updated guidance.
Speaker Change: Before any mitigation.
Speaker Change: You talked about some short term mitigation, so I guess.
Speaker Change: Is there any.
Speaker Change: A material difference.
Speaker Change: Well you can actually do this year all else equal to some of the mitigation strategies that you could put in place before the end of the year to have a different outcome on mitigated.
Speaker Change: <unk>.
Speaker Change: Yes, so Matt we do have some actions we're working through again, we don't want to get ahead of ourselves because we've got we've got to make sure that we can execute through those those plans.
Speaker Change: Until the near term.
Speaker Change: Actions, we're taking but again because this is hitting us kind of in the middle of the year. It makes it very difficult to come out and get too confident in those actions impacting this year.
Speaker Change: Like I said the more we can start to execute some of these mitigation plans and we also need to see some things settle because what you don't want to do is taken take one path and that path gets closed off and you have to go down another path. So we're also being conscious of that but we believe some of these plants can set us up very well as we exit the year and we are.
Speaker Change: Doing everything we can to impact this year as well it just.
Speaker Change: As you know it turns through it goes onto the balance sheet turn through inventories in and Thats why were trying to impacted as quickly as possible.
Speaker Change: Make sure we're set up well for next year, Yes, I think you'd see kind of a tightening of the range is of the core business I mean think about it that way and then just separating out Tara if you compare to kind of how other companies are doing and some people are saying well we would as a guidance. We would have done that and we're just being very transparent about saying that we're kind of showing you the increase.
Speaker Change: Or is that kind of tightening the guidance on the core and then saying, but there is this offset so it's sort of a different approach to a green, but it's also sort of seeing the same thing.
Speaker Change: Can I sneak in one last one just on Michael's last point, there you said through the cadence of the year for the tariff impact 2 million next quarter is the impact on Q3, and Q4 about equal or is it kind of.
Speaker Change: Ratchet up through the year could you help us on that at all.
Speaker Change: Yes, I'd say.
Speaker Change: If you look at Canada high end of the tariff impact range.
Speaker Change: When youre looking from the 33% to 37.
Youll see more of a step up pronounced step up in Q4.
Speaker Change: But it does.
Speaker Change: Within that range it steps up each quarter, but it's more pronounced on the high end of the impact range, just because we're assuming that the reciprocal tariffs start to come into play for Malaysia at 24%. After the 90 day cost period, so that won't start that will now start rolling into.
Speaker Change: Into cost of sales until the fourth quarter.
Speaker Change: Got it thank you very much.
Speaker Change: Youre welcome.
Speaker Change: Your next question comes from the line of Michael Palmer. Please.
Speaker Change: Please go ahead.
Speaker Change: Hey, good afternoon, I have a follow up for Mike on the tender callout in the quarter I just wanted to.
Speaker Change: I understand this so I heard timing of it drove higher than expected capital makes sense, but.
Speaker Change: But it sounded like it also drove lower than expected consumables and I guess I don't need the dots connected there why are the consumables lower than expected on the timing of the of a tender.
Speaker Change: Yes, it's more of the Lumpiness of tenders so.
Speaker Change: Consumable orders were.
Speaker Change: Lighter in the first quarter and.
Speaker Change: And again like I said I mean, if you if you kind of normalize for that we saw very strong growth across the board for our consumable sales.
Speaker Change: And we fully believe that that is going to be a timing issue that's going to start to correct itself in Q2 through Q4. So.
Speaker Change: And that's why we're not it doesn't impact anything to our guidance for the full year.
Speaker Change: Again. These are these are large tenders that can be lumpy, but it's a renewed tender that we've continued to renew each year. So.
Speaker Change: Understood.
Speaker Change: My follow up perhaps for Katy the illusion to changing the sales force model.
Speaker Change: If I understood the comment correct today, your specialized by product there might be benefit and going to more of a generalist.
Speaker Change: Kind of region regionally focused model sell everything instead of just some things and I Wanna.
Speaker Change: Sure I understand that correct at a high level and then.
Speaker Change: I think the related question is is this something I guess theres a worry there's always a worry around salesforce changes that it could be disruptive so what would be the initial benefits your upside or how do you manage.
Katie Szyman: Risk as you do this and is this something that company was considering for awhile or Katie is this kind of.
Katie Szyman: Reflective of your World view, and something <unk> seen out of the gates and have conviction in moving forward on.
Katie Szyman: Yes, Thanks, that's a great question.
Katie Szyman: Same day.
Katie Szyman: Kind of deal with Salesforce and you can either have that generalist model right or you can have the dedicated teams well.
Katie Szyman: We looked at as we evaluated the decision is basically you have very small dedicated team to some of these specialty areas. So for example, the cap <unk> team with a dedicated team of colleagues.
Katie Szyman: I don't know 10 people and instead youre actually instead by Glenn with the generalist model, you'll be able to have all of our sales representatives actually carrying the cap Algraphy bank rate and so it's basically as you start a new product category you always want to have dedicated teams because they can actually.
Katie Szyman: Provide the focus necessary to get that product going but for our advanced monitoring category Captain Orography hemodynamics in brain, we feel like there's enough knowledge at this point that we are going to benefit from having all of the fourth of our sales reps and clinical is actually able to speak to that instead of having these small dedicated team.
Katie Szyman: We just think there will be more leverage from that.
Katie Szyman: So to quantify how it how it is going to transition and obviously any change there's always risk right.
Katie Szyman: We haven't specifically quantified it but we really are optimistic that by retraining and getting our broad sales team is totally engaged in full bag, it's going to be a method.
Katie Szyman: That makes sense.
Speaker Change: Yeah. That's helpful. If I can sneak one last one in on sound is there a tax benefit expected in selling at this price relative to the purchase of the asset. Thank you.
Katie Szyman: Yes, Thanks, Mike.
Katie Szyman: At this price point.
Speaker Change: There is no election benefit here that were that were estimating at this time so.
Speaker Change: Okay.
Operator, that's our last question.
Speaker Change: With that I will turn the call back over to Katie Simon for closing remarks.
Katie Simon: Great well thanks, everyone for your interest in asking now and for participating in the call.
Speaker Change: Just wanted to let you know and look forward to seeing everybody as I had out on the road and it's hard to meet more with investors throughout the quarter. So thanks again, everyone and we'll talk to you next quarter.
Speaker Change: Ladies and gentlemen, this concludes today's conference call. We thank you for participating and ask you. Please disconnect your lines.
Speaker Change: Please wait the conference will begin shortly.
Speaker Change: [music].
Speaker Change: Okay.
Yes.
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: [music].
Speaker Change: Okay.
Yes.
Speaker Change: [music].
Speaker Change: Sure.
Speaker Change: [music].
Speaker Change: Yes.
Speaker Change: Yes.
Speaker Change: [music].
Speaker Change: Sure.
Speaker Change: [music].
Speaker Change: Yes.
Speaker Change: [music].
Speaker Change: Sure.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Sure.
Speaker Change: [music].
Speaker Change: Okay.